Skip to content

Hepatitis B

Two guidelines: EASL 2025 (current European) and AASLD 2018 (US guidance). Both recommend entecavir, tenofovir (TDF or TAF) or PEG-IFNα as first-line treatment.

EASL 2025

International Current

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

Official source

AASLD 2018

International Current

Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance

Official source

Where they differ

EASL 2025 AASLD 2018
Treat chronic hepatitis HBV DNA ≥2,000 IU/mL + ALT >ULN and/or significant fibrosis ALT ≥2 × ULN (or significant histology) + DNA >20,000 (HBeAg+) or >2,000 (HBeAg−)
ALT upper limit Laboratory ULN 35 U/L men, 25 U/L women
Cirrhosis Treat any detectable DNA Treat (compensated with DNA >2,000; decompensated any DNA)
Pregnancy Tenofovir if DNA ≥200,000, start before the third trimester Tenofovir in the third trimester if DNA >200,000

Clinical pearls

  • HBsAg + anti-HBc before any immunosuppression; rituximab is the highest-risk drug.
  • HBeAg-negative chronic hepatitis is commoner in Asia (precore/core-promoter mutants).
  • Always test for HDV in HBsAg-positive patients.